CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 130 enrolled
Drug / intervention
Ticagrelor orodispersible tablets +1 moredrug
Likely dose
Ticagrelor orodispersible tablets 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03822377
NCT03822377Phase 3Completed
CompareCT.gov

Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation

Azienda Ospedaliero Universitaria di Sassari·interventional·Posted Jan 30, 2019·Updated Sep 8, 2021

In Brief

A Phase 3 clinical trial evaluating Ticagrelor orodispersible tablets and Ticagrelor standard tablets for ST Elevation Myocardial Infarction and NSTEMI - Non-ST Segment Elevation MI. Completed, enrolled 130 participants across 1 site.

Detailed Summary

Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST elevation myocardial infarction or very high-risk non-ST elevation myocardial infarction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
CountriesItaly
CollaboratorsAstraZeneca

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 30, 2019
Enrollment StartJun 27, 2019
Primary CompletionAug 31, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.4 years ago

Interventions

Ticagrelor orodispersible tabletsdrug

Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.

Ticagrelor standard tabletsdrug

Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.